IN8bio, Inc. (INAB) stock
INABNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.82−0.00 (-0.04%)
Close on Nov 13, 2026Market cap $8.08MP/E –Yield –
IN8bio EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
IN8bio's EPS for the twelve months ending Sep 30, 2026 was -$1.45. For fiscal 2025 it was -$4.44. The highest annual figure on record is -$4.44 in fiscal 2025.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$4.44 | – |
| FY2024 | Dec 31, 2024 | -$17.05 | – |
| FY2023 | Dec 31, 2023 | -$30.00 | – |
| FY2022 | Dec 31, 2022 | -$40.80 | – |
| FY2021 | Dec 31, 2021 | -$44.10 | – |
| FY2020 | Dec 31, 2020 | -$90.60 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$0.24 | – |
| Q2 FY2026 | Jun 30, 2026 | -$0.25 | – |
| Q1 FY2026 | Mar 31, 2026 | -$0.26 | – |
| Q4 FY2025 | Dec 31, 2025 | -$0.70 | – |
| Q3 FY2025 | Sep 30, 2025 | -$0.85 | – |
| Q2 FY2025 | Jun 30, 2025 | -$1.24 | – |
| Q1 FY2025 | Mar 31, 2025 | -$2.16 | – |
| Q4 FY2024 | Dec 31, 2024 | -$2.37 | – |
| Q3 FY2024 | Sep 30, 2024 | -$4.49 | – |
| Q2 FY2024 | Jun 30, 2024 | -$5.51 | – |
| Q1 FY2024 | Mar 31, 2024 | -$6.00 | – |
| Q4 FY2023 | Dec 31, 2023 | -$6.58 | – |
| Q3 FY2023 | Sep 30, 2023 | -$6.90 | – |
| Q2 FY2023 | Jun 30, 2023 | -$8.10 | – |
| Q1 FY2023 | Mar 31, 2023 | -$9.00 | – |
| Q4 FY2022 | Dec 31, 2022 | -$9.53 | – |
| Q3 FY2022 | Sep 30, 2022 | -$10.20 | – |
| Q2 FY2022 | Jun 30, 2022 | -$11.40 | – |
| Q1 FY2022 | Mar 31, 2022 | -$9.90 | – |
| Q3 FY2021 | Sep 30, 2021 | -$7.50 | – |
| Q2 FY2021 | Jun 30, 2021 | -$30.00 | – |
| Q1 FY2021 | Mar 31, 2021 | -$24.60 | – |
| Q4 FY2020 | Dec 31, 2020 | -$26.37 | – |
| Q3 FY2020 | Sep 30, 2020 | -$18.00 | – |
| Q2 FY2020 | Jun 30, 2020 | -$27.60 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?